Patient Adherence, communications & Stakeholder Engagement - Europe 2011

Venue: Hotel Concorde Berlin

Location: Berlin, Germany

Event Date/Time: May 31, 2011 End Date/Time: Jun 01, 2011
Report as Spam

Description

Our 8th Annual Patient Summit aims to grow on the success of last year by opening up our discussion and looking at the bigger picture, where the patient is at the centre of everything we do. How can we work together to enhance patient communications and engagement to the extent that improved adherence and health outcomes are the simple end result?

Join us in Berlin for the only platform in Europe where key thought leaders and adherence experts can share best-practice ideas and solutions to improve patient outcomes. Find out the latest strategies employed and the key lessons learned.

We have already confirmed some brilliant speakers from top pharma and top stakeholder groups including Ursula Davis, UCB Pharma, Keith Allan, Novartis, Mark Ireland, Boots UK, and Monica Fletcher, European Lung Foundation.

Venue

Augsburger Strasse 41 10789
Berlin
Germany
MORE INFO ON THIS VENUE

Additional Information

You’ll gain insights into: Collaborative efforts and successful partnerships to improve patient outcomes: Key examples of how pharma can effectively communicate, inform and access patients via HCPs and patient groups Focus your adherence and communications strategy on patients’ needs: Increase patient engagement, empowerment and self-management Motivational interviewing and patient psychology: Hear about successful motivational tools in action to ensure behavioural change is self-driven as well as supported for lasting results Integrate adherence tools into your brand strategy for long-term impact: Ensure patient-centricity is part of the mix from drug development through to marketing New communication channels to reach and engage your patient: Online platforms, patient communities and social media insights – How important are they for your brand? Regulations, guidelines and risks involved: Should pharma be allowed to communicate the availability of support and drug information, directly to patients? Patients as the new dominant stakeholder: Convince payers of the long-term investment and value proposition in patient programmes to create a win-win-win for patient, practitioner and payer